Compare Amylx Pharmaceuticals Inc (AMLX) vs Raymond James Financial, Inc. (RJF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs Raymond James Financial, Inc. — how do they compare? Amylx Pharmaceuticals Inc trades at $23.66 (market cap $2.64B), while Raymond James Financial, Inc. trades at $180.34 (market cap $34.63B). The key difference: Raymond James Financial, Inc. is far larger — about 13.1× Amylx Pharmaceuticals Inc's market cap, and Raymond James Financial, Inc. pays a 1.2% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | RJF | |
|---|---|---|
Market Cap | $2.64B | $34.63B |
Sector | Health | Financials |
52-Week High | $24.19 | $180.55 |
52-Week Low | $7.82 | $140.89 |
Enterprise Value | $2.39B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $23.66, up 4.37% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$144.74M in 2025, with negative ROE and ROA, while Q2 2026 EPS missed expectations. Key catalysts include the Phase 3 LUCIDITY trial readout for avexitide expected in late August or early September 2026, as highlighted in recent earnings calls and news.
Analyst consensus is strongly bullish with a $30.00 price target and 91% buy ratings, driven by pipeline potential. However, high cash burn, ongoing losses, and reliance on clinical trial success pose significant risks. The stock offers speculative upside if trials succeed but faces downside from operational challenges and market volatility.
Raymond James Financial (RJF) trades at $179.09, up 1.43% today, with a bullish technical signal and strong earnings momentum after beating Q2 2026 EPS estimates. The stock shows consistent revenue growth, reaching $13.84B in 2025, and a solid net income margin of 15.37%. Recent news highlights record Q3 2026 revenues and strategic acquisitions as key growth drivers.
The outlook is positive with a consensus price target of $183.75, though risks include market volatility and execution of growth initiatives. The stock presents an opportunity based on fundamental strength and analyst support, balanced by the need to monitor expense management and economic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About Raymond James Financial, Inc.
Raymond James Financial is a financial holding company whose major operations include wealth management, investment banking, asset management, and commercial banking. The company has more than 14,000 employees and supports more than 5,000 independent contractor financial advisors across the United States, Canada, and the United Kingdom. Approximately 90% of the company's revenue is from the U.S. and 70% is from the company's wealth-management segment.
Read more on RJF →
